open access

Vol 88, No 6 (2020)
Research paper
Submitted: 2020-05-29
Accepted: 2020-10-15
Published online: 2020-12-16
Get Citation

Study of inflammatory biomarkers in COPD and asthma exacerbations

Alice G Vassiliou1, Vlassios Vitsas2, Matina Kardara1, Chrysi Keskinidou1, Pinelopi Michalopoulou2, Nikoletta Rovina3, Ioanna Dimopoulou4, Stylianos E Orfanos15, Georgios Tsoukalas2, Antonia Koutsoukou3, Anastasia Kotanidou1
DOI: 10.5603/ARM.a2020.0188
·
Pubmed: 33393648
·
Adv Respir Med 2020;88(6):558-566.
Affiliations
  1. 1st Department of Critical Care Medicine & Pulmonary Services, National and Kapodistrian University of Athens, Medical School, Evangelismos Hospital, Athens, Greece, Athens
  2. 4th Pulmonary Department, Sotiria Chest Disease Hospital, Athens, Greece
  3. Centre for Respiratory Failure and Intensive Care Unit, Sotiria Chest Disease Hospital, Athens, Greece
  4. 1st Department of Critical Care Medicine & Pulmonary Services, National and Kapodistrian University of Athens, Medical School, Evangelismos Hospital, Athens, Greece
  5. 2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Athens, Greece

open access

Vol 88, No 6 (2020)
ORIGINAL PAPERS
Submitted: 2020-05-29
Accepted: 2020-10-15
Published online: 2020-12-16

Abstract

Introduction: Exacerbations are critical events in the course of asthma and chronic obstructive pulmonary disease (COPD). These events are potentially life-threatening, and the studies have shown that they have tremendous implications on long-term disease control and the overall prognosis of the patients. The aim of this study was to examine adipokines, cytokines and C-reactive protein (CRP) as potential biomarkers in asthma and COPD.
Material and methods: Prospective cohort study of COPD and asthma patients treated for acute exacerbations. Thirty-nine COPD patients and 15 asthmatic patients were included in the study. Leptin, adiponectin, resistin, interleukin (Il)-6, 8, 18, tumor necrosis factor-a (TNF-a), and CRP were measured at three time points: on admission, at resolution and at the stable phase. Pre- and post-bronchodilation spirometry was additionally performed at resolution and at the stable phase.
Results: In COPD patients, leptin, leptin/adiponectin (L/A) ratio and resistin were elevated on admission compared to the stable phase. In asthmatic patients, leptin levels were raised on admission compared to the stable phase, and adiponectin was elevated at resolution compared to admission. In both diseases, CRP was significantly increased on admission compared to both resolution and stable disease. Finally, TNF-a could distinguish between asthma and COPD stable phase.
Conclusions: Leptin and CRP levels may be useful biomarkers in monitoring COPD and asthma response to treatment during an exacerbation episode. Hypoadiponectinemia was detected in asthma and COPD during all stages of the diseases. TNF-a could distinguish between asthma and COPD stable phase.

Abstract

Introduction: Exacerbations are critical events in the course of asthma and chronic obstructive pulmonary disease (COPD). These events are potentially life-threatening, and the studies have shown that they have tremendous implications on long-term disease control and the overall prognosis of the patients. The aim of this study was to examine adipokines, cytokines and C-reactive protein (CRP) as potential biomarkers in asthma and COPD.
Material and methods: Prospective cohort study of COPD and asthma patients treated for acute exacerbations. Thirty-nine COPD patients and 15 asthmatic patients were included in the study. Leptin, adiponectin, resistin, interleukin (Il)-6, 8, 18, tumor necrosis factor-a (TNF-a), and CRP were measured at three time points: on admission, at resolution and at the stable phase. Pre- and post-bronchodilation spirometry was additionally performed at resolution and at the stable phase.
Results: In COPD patients, leptin, leptin/adiponectin (L/A) ratio and resistin were elevated on admission compared to the stable phase. In asthmatic patients, leptin levels were raised on admission compared to the stable phase, and adiponectin was elevated at resolution compared to admission. In both diseases, CRP was significantly increased on admission compared to both resolution and stable disease. Finally, TNF-a could distinguish between asthma and COPD stable phase.
Conclusions: Leptin and CRP levels may be useful biomarkers in monitoring COPD and asthma response to treatment during an exacerbation episode. Hypoadiponectinemia was detected in asthma and COPD during all stages of the diseases. TNF-a could distinguish between asthma and COPD stable phase.

Get Citation

Keywords

COPD; asthma; biomarkers; adipokines; cytokines

About this article
Title

Study of inflammatory biomarkers in COPD and asthma exacerbations

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 6 (2020)

Article type

Research paper

Pages

558-566

Published online

2020-12-16

DOI

10.5603/ARM.a2020.0188

Pubmed

33393648

Bibliographic record

Adv Respir Med 2020;88(6):558-566.

Keywords

COPD
asthma
biomarkers
adipokines
cytokines

Authors

Alice G Vassiliou
Vlassios Vitsas
Matina Kardara
Chrysi Keskinidou
Pinelopi Michalopoulou
Nikoletta Rovina
Ioanna Dimopoulou
Stylianos E Orfanos
Georgios Tsoukalas
Antonia Koutsoukou
Anastasia Kotanidou

References (25)
  1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017; 195(5): 557–582.
  2. Global initiative for astha. Global Strategy for Asthma Management and Prevention. 2017.
  3. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11(2): 85–97.
  4. Chan KH, Yeung SC, Yao TJ, et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(9): 1193–1200.
  5. Kirdar S, Serter M, Ceylan E, et al. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest. 2009; 69(2): 219–224.
  6. Tomoda K, Yoshikawa M, Itoh T, et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest. 2007; 132(1): 135–140.
  7. Mutairi SAl, Mojiminiyi O, Shihab-Eldeen A, et al. Putative roles of circulating resistin in patients with asthma, COPD and cigarette smokers. Disease Markers. 2011; 31(1): 1–7.
  8. Sood A, Shore SA. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies. J Allergy (Cairo). 2013; 2013: 785835.
  9. Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017; 26(143).
  10. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008; 118(11): 3546–3556.
  11. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006; 2(6): 318–327.
  12. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012; 94(10): 2137–2142.
  13. Zouki C, Beauchamp M, Baron C, et al. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest. 1997; 100(3): 522–529.
  14. Ballou S, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992; 4(5): 361–368.
  15. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 162(4 Pt 1): 1239–1245.
  16. Kythreotis P, Kokkini A, Avgeropoulou S, et al. Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2009; 9: 11.
  17. Sood A, Ford ES, Camargo CA. Association between leptin and asthma in adults. Thorax. 2006; 61(4): 300–305.
  18. Jamaluddin MdS, Weakley SM, Yao Q, et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012; 165(3): 622–632.
  19. Kumor‑Kisielewska A, Kierszniewska‑Stępień D, Pietras T, et al. Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary disease. Polish Archives of Internal Medicine. 2013; 123(5): 215–220.
  20. Wang QY, Zhang H, Yan X, et al. Serum resistin and leptin in patients with chronic obstructive pulmonary disease and their relationship to nutritional state. . Zhonghua Jie He He Hu Xi Za Zhi. 2005; 28(7): 445–447.
  21. Rojas-Dotor S, Segura-Méndez NH, Miyagui-Namikawa K, et al. Expression of resistin, CXCR3, IP-10, CCR5 and MIP-1α in obese patients with different severity of asthma. Biol Res. 2013; 46(1): 13–20.
  22. Chen YWR, Leung JM, Sin DD. A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS One. 2016; 11(7): e0158843.
  23. Liu HC, Lu MC, Lin YC, et al. Differences in IL-8 in serum and exhaled breath condensate from patients with exacerbated COPD or asthma attacks. J Formos Med Assoc. 2014; 113(12): 908–914.
  24. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153(2): 530–534.
  25. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010; 181(4): 315–323.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl